Medicare Enrolled
Dr. Venumadhav Kotla, M.D.
Hematology · Gainesville, GA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Mixed engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kotla from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kotla?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kotla
Dr. Venumadhav Kotla is a hematology specialist in Gainesville, GA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Kotla performed 14,693 Medicare services across 1,198 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kotla received a total of $16,159 from 67 pharmaceutical and/or device companies across 405 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kotla is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 12% volume in GA
$16,159 industry payments
Medicare Practice Summary
Medicare Utilization ↗14,693
Medicare services
Top 12% in GA for hematology
1,198
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~816 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
7,800 | $0 | $5 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,840 | $0 | $2 |
| Injection, granisetron hydrochloride, 100 mcg | 1,380 | $0 | $10 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
660 | $8 | $45 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
510 | $10 | $65 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
506 | $8 | $30 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
469 | $65 | $115 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
206 | $87 | $650 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
185 | $81 | $160 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
170 | $20 | $95 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
135 | $10 | $40 |
| Annual depression screening | 121 | $17 | $40 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
103 | $71 | $115 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
87 | $44 | $350 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
80 | $1 | $10 |
| PSA test (prostate cancer screening) | 69 | $18 | $115 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
54 | $16 | $100 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
49 | $81 | $165 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
41 | $6 | $25 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
39 | $95 | $570 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
34 | $19 | $70 |
| Free thyroxine (T4) test A blood test that measures the level of free thyroxine, a thyroid hormone, in the bloodstream. |
34 | $9 | $75 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
34 | $19 | $175 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
26 | $120 | $245 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
24 | $62 | $242 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
20 | $64 | $236 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
17 | $38 | $113 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.2% high complexity
76.7% medium
20.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$16,159
Total received (2018-2024)
Avg $2,308/year across 7 years
Top 32% in GA for hematology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
67
Companies
405
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,429 (46.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$6,000 (37.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,879 (11.6%)
Other
Charitable contributions, space rental, and other categories
$851 (5.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,399
2023
$4,425
2022
$6,210
2021
$12
2020
$92
2019
$1,707
2018
$314
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$851
AstraZeneca Pharmaceuticals LP
$597
Merck Sharp & Dohme LLC
$216
PFIZER INC.
$202
ABBVIE INC.
$197
Janssen Biotech, Inc.
$171
Daiichi Sankyo Inc.
$154
Celgene Corporation
$128
GlaxoSmithKline, LLC.
$117
Takeda Pharmaceuticals U.S.A., Inc.
$101
Regeneron Healthcare Solutions, Inc.
$78
GENZYME CORPORATION
$60
Bayer Healthcare Pharmaceuticals Inc.
$57
Lilly USA, LLC
$50
Gilead Sciences, Inc.
$47
BeiGene USA, Inc.
$47
Exelixis Inc.
$43
E.R. Squibb & Sons, L.L.C.
$35
Astellas Pharma US Inc
$31
Deciphera Pharmaceuticals Inc.
$28
Sumitomo Pharma America, Inc.
$26
Eisai Inc.
$25
Alexion Pharmaceuticals, Inc.
$24
Stemline Therapeutics Inc.
$24
TAIHO ONCOLOGY, INC.
$23
Aveo Pharmaceuticals, Inc.
$22
Geron Corporation
$18
ARRAY BIOPHARMA INC
$14
Dendreon Pharmaceuticals LLC
$13
Top 3 companies account for 48.9% of 2024 payments
All-time payments by company (2018-2024) ›
Kite Pharma, Inc.
$3,256
Janssen Biotech, Inc.
$2,160
Daiichi Sankyo Inc.
$1,304
Novartis Pharmaceuticals Corporation
$1,083
AstraZeneca Pharmaceuticals LP
$833
Merck Sharp & Dohme LLC
$659
BeiGene USA, Inc.
$572
Celgene Corporation
$565
PFIZER INC.
$555
Seagen Inc.
$400
Genentech USA, Inc.
$300
ABBVIE INC.
$284
GENZYME CORPORATION
$269
Exelixis Inc.
$259
GlaxoSmithKline, LLC.
$257
Astellas Pharma US Inc
$253
Amgen Inc.
$210
E.R. Squibb & Sons, L.L.C.
$200
Novocure GmbH
$200
Gilead Sciences, Inc.
$198
Takeda Pharmaceuticals U.S.A., Inc.
$143
Lilly USA, LLC
$136
Eisai Inc.
$125
Regeneron Healthcare Solutions, Inc.
$121
Blueprint Medicines Corporation
$113
Karyopharm Therapeutics Inc.
$113
Bayer HealthCare Pharmaceuticals Inc.
$102
Foundation Medicine, Inc.
$101
Bayer Healthcare Pharmaceuticals Inc.
$101
Deciphera Pharmaceuticals Inc.
$80
EISAI INC.
$78
Stemline Therapeutics Inc.
$61
Merck Sharp & Dohme Corporation
$57
Boehringer Ingelheim Pharmaceuticals, Inc.
$56
Incyte Corporation
$54
Sumitomo Pharma America, Inc.
$53
MorphoSys, US Inc.
$53
ARRAY BIOPHARMA INC
$51
CTI BioPharma Corp.
$51
Rigel Pharmaceuticals, Inc.
$48
Puma Biotechnology, Inc.
$45
AVEO Pharmaceuticals, Inc.
$43
ADC Therapeutics America, Inc.
$43
Epizyme, Inc.,
$39
Alexion Pharmaceuticals, Inc.
$38
G1 Therapeutics, Inc.
$33
Agios Pharmaceuticals, Inc.
$30
Sobi, Inc
$28
Blue Earth Diagnostics Limited
$25
TAIHO ONCOLOGY, INC.
$23
Pharmacyclics LLC, an AbbVie Company
$22
EMD Serono, Inc.
$22
Aveo Pharmaceuticals, Inc.
$22
Organon LLC
$21
Mirati Therapeutics, Inc.
$21
Epizyme, Inc.
$21
Biocompatibles, Inc.
$20
Geron Corporation
$18
Kyowa Kirin, Inc.
$17
Coherus Biosciences Inc.
$17
SERVIER PHARMACEUTICALS LLC
$16
MACROGENICS, INC.
$14
PUMA BIOTECHNOLOGY, INC.
$14
Seattle Genetics, Inc.
$14
Acrotech Biopharma LLC
$13
Dendreon Pharmaceuticals LLC
$13
AbbVie, Inc.
$13
Top 3 companies account for 41.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AYVAKIT · Abraxane · Alecensa · Axumin · BAVENCIO · BELEODAQ · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · ELITEK · ELREXFIO · ENHERTU · EPKINLY · ERLEADA · Enhertu · Erleada · FASLODEX · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE CDX · FOUNDATIONONE LIQUID CDX · Fabhalta · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUPRON DEPOT · LYNPARZA · Lenvima · Lunsumio · MARGENZA · MEKINIST · MONJUVI · NERLYNX · NINLARO · Neulasta · Nplate · Nubeqa · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Orserdu · PADCEV · PEMAZYRE · PLUVICTO · PREVNAR 20 · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RYBREVANT · RYTELO · Rezlidhia · SARCLISA · SCEMBLIX · SHINGRIX · Stivarga · TALVEY · TAZVERIK · TECENTRIQ · TECVAYLI · THERASPHERE-BIO · TIVDAK · TUKYSA · Tazverik · Tecartus · Tibsovo · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · Venclexta · Vonjo · XALKORI · XPOVIO · XTANDI · Xofigo · Yescarta · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (46%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematologists within 10 mi
7
Per 100K population
3.4
County median income
$77,430
Nearest hospital
NORTHEAST GEORGIA MEDICAL CENTER, INC
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kotla is a mixed practice specialist, with above-average Medicare volume (top 12% in GA), with mixed engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kotla experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Kotla performed 7,800 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kotla receive payments from pharmaceutical companies?
Yes. Dr. Kotla received a total of $16,159 from 67 companies across 405 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kotla's costs compare to other hematologists in Gainesville?
Dr. Kotla's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kotla) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologists in Gainesville
Browse hematologists in Gainesville ranked by procedure volume and transparency data.
Highest volume
Top Hematologists in GA
Hematologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologists in GA
Which GA hematologists receive the most from drug and device companies.
By company
Kite Pharma, Inc. Payments to Doctors
See all physicians who received payments from Kite Pharma, Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology